Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients
OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round. The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with additi
<p>OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round. The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with additi</p>